Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19371037 | 0.89 | MAPT (0.46) | MAPTLMNAPOLBMAOBTSHR | |
| SCHEMBL26350901 | 0.85 | MAPT (0.48) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL29664059 | 0.83 | NOS1 (0.49) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL18183739 | 0.79 | TSHR (0.49) | MAPTCYP3A4LMNAPOLBMAOB | |
| SCHEMBL11680975 | 0.77 | MAPT (0.59) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL1273838 | 0.77 | TSHR (0.55) | MAPTLMNAALOX15L3MBTL1TSHR | |
| SCHEMBL15687581 | 0.77 | TSHR (0.47) | MAPTPOLBMAOBTSHRSMN1; SMN2 | |
| SCHEMBL357408 | 0.77 | AXL (0.56) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL11484322 | 0.77 | NOS1 (0.49) | MAPTNOS1CYP3A4LMNAALOX15 | |
| SCHEMBL31041189 | 0.77 | TSHR (0.55) | MAPTLMNAALOX15L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260085057-A1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | Bayer Pharma AG (DE) | 2026-03-26 | — | — | US | disclosed |
| US-12559473-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260008776-A1 | CRYSTAL FORM AND SALT FORM OF FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12459916-B2 | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-11-04 | — | — | US | disclosed |
| EP-4638420-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| EP-3083586-A1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016083433-A1 | NEW SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016083433-A1 | NEW SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | WO | disclosed |
| WO-2015091426-A1 | NOVEL CARBOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND USE THEREOF FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-5928998-A | PRE- AND POSTEMERGENCE HERBICIDES | ZENECA LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5444038-A | Arylindazoles and their use as herbicides | ZENECA LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| CN-1079961-A | New arylindazoles and they are as the purposes of weedicide | SERIAL (GB) | 1993-12-29 | — | — | CN | disclosed |
| WO-1993018008-A1 | NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES | ZENECA LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | MAPT 3470/4885NOS1 1461/4885CYP3A4 3598/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885NOS1 3662/4885CYP3A4 2542/4885 |
| US-12459916-B2 | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | AADAC, IDO1, HRH4 | MAPT 1294/4885NOS1 508/4885CYP3A4 118/4885 |
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | IRAK4, IRAK1, IRAK2 | MAPT 3920/4885NOS1 2466/4885CYP3A4 380/4885 |
| US-20260085057-A1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | HRH4, BRCA1, HRH1 | MAPT 3835/4885NOS1 715/4885CYP3A4 371/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | MAPT 4151/4885NOS1 1727/4885CYP3A4 1164/4885 |
| US-12559473-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | CPT1A, CYP11B1, CYP11B2 | MAPT 3599/4885NOS1 2706/4885CYP3A4 125/4885 |
| US-20160311833-A1 | NOVEL INDAZOLECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS COMPRISING THEM AND THEIR USE FOR PRODUCING MEDICAMENTS | MALT1, APC, UACA | MAPT 534/4885NOS1 1823/4885CYP3A4 45/4885 |
| US-20260008776-A1 | CRYSTAL FORM AND SALT FORM OF FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE | IRAK4, FLT3, IRAK2 | MAPT 1364/4885NOS1 2758/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.